Literature DB >> 19498074

Duration of antidepressant drug treatment and its influence on risk of relapse/recurrence: immortal and neglected time bias.

Helga Gardarsdottir1, Toine C Egberts, Joost J Stolker, Eibert R Heerdink.   

Abstract

Several observational studies have found a higher risk of recurrence/relapse of depression for patients who discontinue antidepressant use compared with those who continue. This study demonstrated that measurement of follow-up time can be subject to immortal and neglected time bias. Data were obtained from the 2001 Second Dutch National Survey of General Practice. The study population was composed of antidepressant users with a registered depression diagnosis, divided into early discontinuers and continuing users. Two methods were used to measure time to relapse/recurrence. Method 1, used in previously mentioned studies, measured the beginning of follow-up 6 months after starting antidepressant therapy. Method 2 constructed individual treatment episodes for each patient and measured follow-up from actual end-of-treatment episode. The Cox proportional hazards model produced a risk ratio of 1.58 (95% confidence interval: 1.02, 2.45) for method 1, suggesting a higher risk of relapse/recurrence for early discontinuers. In method 2, a statistically nonsignificant risk ratio of 0.77 (95% confidence interval: 0.49, 1.21) was produced, indicating no difference in risk of relapse/recurrence. The authors found the method used in previous studies subject to bias. Applying a different method, accounting for immortal and neglected time bias, eliminated the protective effects of longer treatments.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19498074     DOI: 10.1093/aje/kwp142

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  13 in total

1.  Invited Commentary: Assessing treatment effects by using observational analyses--opportunities and limitations.

Authors:  Philip S Wang; Michael Schoenbaum
Journal:  Am J Epidemiol       Date:  2009-06-04       Impact factor: 4.897

2.  Methods for constructing treatment episodes and impact on exposure-outcome associations.

Authors:  Laura Pazzagli; Lena Brandt; Marie Linder; David Myers; Panagiotis Mavros; Morten Andersen; Shahram Bahmanyar
Journal:  Eur J Clin Pharmacol       Date:  2019-11-22       Impact factor: 2.953

3.  Treatment duration with selective serotonin reuptake inhibitors among children and adolescents in Finland: a nationwide register study.

Authors:  Leena K Saastamoinen; Mika Wallin; Piia Lavikainen; Marja S Airaksinen; Andre Sourander; J Simon Bell
Journal:  Eur J Clin Pharmacol       Date:  2012-02-12       Impact factor: 2.953

4.  Behavioural activation therapy for depression in adults with non-communicable diseases.

Authors:  Eleonora Uphoff; Malini Pires; Corrado Barbui; Deepa Barua; Rachel Churchill; Doriana Cristofalo; David Ekers; Edward Fottrell; Papiya Mazumdar; Marianna Purgato; Rusham Rana; Judy Wright; Najma Siddiqi
Journal:  Cochrane Database Syst Rev       Date:  2020-08-06

Review 5.  Methods for time-varying exposure related problems in pharmacoepidemiology: An overview.

Authors:  Laura Pazzagli; Marie Linder; Mingliang Zhang; Emese Vago; Paul Stang; David Myers; Morten Andersen; Shahram Bahmanyar
Journal:  Pharmacoepidemiol Drug Saf       Date:  2017-12-28       Impact factor: 2.890

Review 6.  Barriers to discontinuing antidepressants in patients with depressive and anxiety disorders: a review of the literature and clinical recommendations.

Authors:  Willemijn Scholten; Neeltje Batelaan; Anton Van Balkom
Journal:  Ther Adv Psychopharmacol       Date:  2020-06-10

7.  Antidepressants in primary care: patients' experiences, perceptions, self-efficacy beliefs, and nonadherence.

Authors:  Hans Wouters; Marcel L Bouvy; Erica Cg Van Geffen; Helga Gardarsdottir; Anne M Stiggelbout; Liset Van Dijk
Journal:  Patient Prefer Adherence       Date:  2014-02-10       Impact factor: 2.711

Review 8.  Methodological Flaws, Conflicts of Interest, and Scientific Fallacies: Implications for the Evaluation of Antidepressants' Efficacy and Harm.

Authors:  Michael P Hengartner
Journal:  Front Psychiatry       Date:  2017-12-07       Impact factor: 4.157

9.  Drug exposure in register-based research-An expert-opinion based evaluation of methods.

Authors:  Antti Tanskanen; Heidi Taipale; Marjaana Koponen; Anna-Maija Tolppanen; Sirpa Hartikainen; Riitta Ahonen; Jari Tiihonen
Journal:  PLoS One       Date:  2017-09-08       Impact factor: 3.240

Review 10.  Risk of relapse after antidepressant discontinuation in anxiety disorders, obsessive-compulsive disorder, and post-traumatic stress disorder: systematic review and meta-analysis of relapse prevention trials.

Authors:  Neeltje M Batelaan; Renske C Bosman; Anna Muntingh; Willemijn D Scholten; Klaas M Huijbregts; Anton J L M van Balkom
Journal:  BMJ       Date:  2017-09-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.